Research Analysts Set Expectations for Curis Q1 Earnings

Curis, Inc. (NASDAQ:CRIS) – Investment analysts at HC Wainwright issued their Q1 2025 EPS estimates for Curis in a research report issued on Monday, March 31st. HC Wainwright analyst E. White forecasts that the biotechnology company will post earnings of ($1.39) per share for the quarter. HC Wainwright has a “Buy” rating and a $16.00 price objective on the stock. The consensus estimate for Curis’ current full-year earnings is ($7.12) per share. HC Wainwright also issued estimates for Curis’ Q2 2025 earnings at ($0.88) EPS, Q3 2025 earnings at ($0.83) EPS, Q4 2025 earnings at ($0.87) EPS, FY2025 earnings at ($3.82) EPS, FY2026 earnings at ($2.98) EPS and FY2027 earnings at ($2.87) EPS.

Curis (NASDAQ:CRIS) last posted its quarterly earnings data on Monday, March 31st. The biotechnology company reported ($1.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.36) by $0.11. The company had revenue of $2.70 million during the quarter, compared to analysts’ expectations of $2.04 million. Curis had a negative return on equity of 923.37% and a negative net margin of 443.35%.

Separately, StockNews.com assumed coverage on shares of Curis in a research note on Saturday, March 29th. They issued a “hold” rating for the company.

Curis Price Performance

NASDAQ:CRIS opened at $1.48 on Thursday. The firm has a market cap of $12.53 million, a price-to-earnings ratio of -0.19 and a beta of 3.49. The firm’s fifty day moving average price is $2.94 and its 200 day moving average price is $3.82. Curis has a 1-year low of $1.40 and a 1-year high of $17.49.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Squarepoint Ops LLC acquired a new position in shares of Curis in the fourth quarter worth $35,000. Millennium Management LLC increased its position in Curis by 92.6% during the 4th quarter. Millennium Management LLC now owns 25,557 shares of the biotechnology company’s stock worth $78,000 after purchasing an additional 12,287 shares in the last quarter. Focused Wealth Management Inc raised its stake in Curis by 9.5% in the 4th quarter. Focused Wealth Management Inc now owns 59,204 shares of the biotechnology company’s stock valued at $181,000 after purchasing an additional 5,138 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Curis by 27.3% in the 4th quarter. Geode Capital Management LLC now owns 83,129 shares of the biotechnology company’s stock valued at $254,000 after purchasing an additional 17,820 shares in the last quarter. Finally, Alyeska Investment Group L.P. acquired a new stake in shares of Curis during the 4th quarter worth about $607,000. 29.97% of the stock is currently owned by institutional investors and hedge funds.

About Curis

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.